• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Systematic review and meta-analysis of statin-induced reduction in LDL-C demonstrates modest absolute benefits

byZoya GomesandMichael Pratte
April 7, 2022
in Cardiology, Chronic Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. This systematic review and meta-analysis found a modest absolute risk reduction of 0.8% in all-cause mortality from statin-induced therapy aimed at reducing low-density lipoprotein cholesterol (levels to improve cardiovascular outcomes.

2. Based on the results of this study, calculated absolute and relative risk reduction benefits should be interpreted with caution due to the presence of significant clinical and statistical heterogeneity among included trials.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Low-density lipoprotein cholesterol (LDL-C) has the ability to accumulate in vessel walls and is a causative factor for the development of atherosclerotic cardiovascular disease. The reduction of LDL-C has become a target for prevention, however the association between statin-induced reduction in LDL-C and the absolute risk reduction (ARR) of individual outcomes such as all-cause mortality, and acute cardiac events is unclear. This systematic review and meta-analysis investigated the association between statin-induced reductions in LDL-C and the ARRs in individual clinical outcomes. The primary outcome was all-cause mortality and secondary outcomes included myocardial infarction and stroke. A total of 21 large randomized clinical trials (RCTs) examining the effectiveness of statins in men and women older than 18 years were included. A meta-analysis was conducted on 19 of the 21 included studies. Meta-analyses showed the ARR to be 0.8% for all-cause mortality, 1.3% for myocardial infarction, and 0.4% for stroke. The relative risk reduction (RRR) for the same clinical outcomes was found to be 9%, 29%, and 14%, respectively. Overall, the ARR of statin-induced therapy was modest in comparison to the RRR in terms of individual clinical outcomes, and no evidence of a conclusive association was found. These findings highlight the importance of discussing ARRs during shared decision making between clinicians and patients. A major strength of this review was the evaluation of individual clinical outcomes, rather than composite outcomes which tend to be inconstantly defined and inadequately reported. A limitation to this study however, was the significant clinical and statistical heterogeneity of the included RCTs.

Click to read the study in JAMA Internal Medicine

Relevant Reading: Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions

In-Depth [systematic review and meta-analysis]: This systematic review and meta-analysis investigated the absolute and relative risk reduction in total mortality and cardiovascular events achieved with statin therapy. An initial database search of PubMed and Embase identified 275 studies, with an additional 31 studies identified from other sources. Of these, 36 studies were selected for full-text review of which, 21 studies were included in this review for quantitative synthesis. Included studies were RCTs that examined the efficacy of statin therapy on total mortality and cardiovascular outcomes within a population size greater than 1000 participants, and with a placebo comparator. Meta-analyses demonstrated reductions in the ARR of 0.8% (95% CI, 0.4%-1.2%, p=.11) for all-cause mortality, 1.3% (95% CI, 0.9%-1.7%, p= <.001) for myocardial infarction, and 0.4% (95% CI, 0.2%-0.6%, p=.14) for stroke, across 21 trials with a study population randomized to receive treatment with statins. Using the same outcomes, the RRR was found to be 9% (95% CI, 5%-14%, p=.01), 29% (95% CI, 22%-34%, p=.07), and 14% (95%CI, 5%-22%, p=.01) respectively. The unadjusted meta-regression analyses demonstrated a weak association between the absolute LDL-C reductions and clinical outcomes. However, upon adjusting for study population and length of follow-up, evidence of an association was found for the relative effect on all-cause mortality, and stroke. The meta-regression was found to be inconclusive in terms of the association between statin-induced LDL-C reduction and all-cause mortality, myocardial infarction, and stroke.

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Associations remain inconclusive between religiosity and spirituality on medication adherence in cardiovascular disease

Aberrant levels of B12 and folate may be associated with increased risk of cardiovascular death in patients with diabetes

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascularcardiovascular riskstatinstatin therapystatins
Previous Post

Overdoses in youth with benzodiazepine and stimulant prescriptions

Next Post

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Cardiology

Associations remain inconclusive between religiosity and spirituality on medication adherence in cardiovascular disease

May 16, 2022
Cardiology

Aberrant levels of B12 and folate may be associated with increased risk of cardiovascular death in patients with diabetes

April 4, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Wellness

Wellness Check: Nutrition

March 31, 2022
Next Post
Large spike in drug use-associated infective endocarditis linked with opioid epidemic

Accessible hepatitis C care for people who inject drugs provide significantly higher rates of cure compared to conventional care

2 Minute Medicine Rewind October 21, 2019

Telehealth may increase access to substance use treatment during COVID-19

Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial

Rates of recurrent ischemic stroke among young adults with prior embolic stroke of undetermined source– the Young ESUS longitudinal cohort study

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.